This review explores cytopenia after CAR T-cell therapy, including its risk stratification and management with growth factors, thrombopoietin-receptor agonists, and hematopoietic stem cell boosts.
Mary McGann, PharmD, BCOP
Advertisement
Articles by Mary McGann, PharmD, BCOP
Advertisement
Latest Updated Articles
Management of Cytopenia Post CAR T-Cell TherapyPublished: August 15th 2024 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
COVID-19 mRNA Vaccines May Boost Immunotherapy Response in Cancer
2
KEYNOTE Trial Data Presented at ESMO 2025 Congress Reiterate Pembrolizumab’s Benefits in NSCLC
3
Court Ruling Highlights Risks of Improper Dose Adjustments
4
States Push Forward on Insurance Mandates for GLP-1 and Obesity Treatments
5
